- Conditions
- Coronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral, Valve Regurgitation, Tricuspid
- Interventions
- Exparel Injectable Product, Bupivacaine Hydrochloride
- Drug
- Lead sponsor
- Kathirvel Subramaniam
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced May 22, 2026, 4:16 AM EDT